The use of ROC analysis for the qualitative prediction of human oral bioavailability from animal data

Pharmaceutical Research

Volumn 31, Issue 3, 2014, Pages 720-730

  Olivares Morales, Andrés ^a   Hatley, Oliver J D ^a   Turner, David ^b   Galetin, Aleksandra ^a   Aarons, Leon ^a   Rostami Hodjegan, Amin ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CERTARA UK LIMITED   (United Kingdom)

Author keywords

BDDCS; interspecies; oral bioavailability; qualitative prediction; ROC analysis

Indexed keywords

AREA UNDER THE CURVE; ARTICLE; COST BENEFIT ANALYSIS; DOG; DRUG BIOAVAILABILITY; DRUG CLASSIFICATION; DRUG DISPOSITION; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FIRST PASS EFFECT; HUMAN; MOUSE; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RAT; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; DOGS; HUMANS; MICE; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; RATS; ROC CURVE;

EID: 84895503393     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1193-2     Document Type: Article

References (39)

1. Lin JH. Species similarities and differences in pharmacokinetics. Drug Metab Dispos. 1995;23:1008-21.
2. Jamei M, Marciniak S, Feng K, Barnett A, Tucker G, Rostami-Hodjegan A. The Simcyp® population-based ADME simulator. Expert Opin Drug Metab Toxicol. 2009;5:211-23.
3. Hellriegel ET, Bjornsson TD, Hauck WW. Interpatient variability in bioavailability is related to the extent of absorption: implications for bioavailability and bioequivalence studies. Clin Pharmacol Ther. 1996;60:601-7.
4. Sietsema WK. The absolute oral bioavailability of selected drugs. Int J Clin Pharmacol Ther Toxicol. 1989;27:179-211.
5. Chhabra RS, Pohl RJ, Fouts JR. A comparative study of xenobiotic-metabolizing enzymes in liver and intestine of various animal species. Drug Metab Dispos. 1974;2:443-7.
6. Nishimuta H, Nakagawa T, Nomura N, Yabuki M. Species differences in hepatic and intestinal metabolic activities for 43 human cytochrome P450 substrates between humans and rats or dogs. Xenobiotica. 2013. doi: 10.3109/00498254.2013.787155.
7. Nishimuta H, Sato K, Mizuki Y, Yabuki M, Komuro S. Species differences in intestinal metabolic activities of cytochrome P450 isoforms between cynomolgus monkeys and humans. Drug Metab Pharmacokinet. 2011;26:300-6.
8. Zamek-Gliszczynski MJ, Lee CA, Poirier A, Bentz J, Chu X, Ellens H, et al. ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans. Clin Pharmacol Ther. 2013;94:64-79.
9. Akabane T, Tabata K, Kadono K, Sakuda S, Terashita S, Teramura T. A comparison of pharmacokinetics between humans and monkeys. Drug Metab Dispos. 2010;38:308-16.
10. Cao X, Gibbs S, Fang L, Miller H, Landowski C, Shin H-C, et al. Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm Res. 2006;23:1675-86.
11. Bueters T, Juric S, Sohlenius-Sternbeck AK, Hu Y, Bylund J. Rat poorly predicts the combined non-absorbed and presystemically metabolized fractions in the human. Xenobiotica. 2013;43:607-16.
12. Chiou WL, Barve A. Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats. Pharm Res. 1998;15:1792-5.
13. Chiou WL, Buehler PW. Comparison of oral absorption and bioavailability of drugs between monkey and human. Pharm Res. 2002;19:868-74.
14. Zhao YH, Abraham MH, Le J, Hersey A, Luscombe CN, Beck G, et al. Evaluation of rat intestinal absorption data and correlation with human intestinal absorption. Eur J Med Chem. 2003;38:233-43.
15. Grass GM, Sinko PJ. Physiologically-based pharmacokinetic simulation modelling. Adv Drug Deliv Rev. 2002;54:433-51.
16. Musther H, Olivares-Morales A, Hatley OJD, Liu B, and Rostami-Hodjegan A. Animal versus human oral drug bioavailability: do they correlate? Eur J Pharm Sci. 2013. doi: 10.1016/j.ejps.2013.08.018.
17. Takahashi M, Washio T, Suzuki N, Igeta K, Yamashita S. The species differences of intestinal drug absorption and first-pass metabolism between cynomolgus monkeys and humans. J Pharm Sci. 2009;98:4343-53.
18. Ward KW, Nagilla R, Jolivette LJ. Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human. Xenobiotica. 2005;35:191-210.
19. Caldwell GW, Ritchie DM, Masucci JA, Hageman W, Yan Z. The new pre-preclinical paradigm: compound optimization in early and late phase drug discovery. Curr Top Med Chem. 2001;1:353-66.
20. Thomas VH, Bhattachar S, Hitchingham L, Zocharski P, Naath M, Surendran N, et al. The road map to oral bioavailability: an industrial perspective. Expert Opin Drug Metab Toxicol. 2006;2:591-608.
21. Wu C-Y, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res. 2005;22:11-23.
22. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413-20.
23. Broccatelli F, Cruciani G, Benet LZ, Oprea TI. BDDCS Class prediction for new molecular entities. Mol Pharm. 2012;9:570-80.
24. Chen ML, Amidon GL, Benet LZ, Lennernas H, Yu LX, The BCS. BDDCS, and regulatory guidances. Pharm Res. 2011;28:1774-8.
25. Benet LZ. The role of BCS (biopharmaceutics classification system) and BDDCS (biopharmaceutics drug disposition classification system) in drug development. J Pharm Sci. 2013;102:34-42.
26. Benet LZ. Predicting drug disposition via application of a biopharmaceutics drug disposition classification system. Basic Clin Pharmacol Toxicol. 2010;106:162-7.
27. Custodio JM, Wu CY, Benet LZ. Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv Drug Deliv Rev. 2008;60:717-33.
28. Benet L, Amidon G, Barends D, Lennernäs H, Polli J, Shah V, et al. The use of BDDCS in classifying the permeability of marketed drugs. Pharm Res. 2008;25:483-8.
29. Shugarts S, Benet LZ. The role of transporters in the pharmacokinetics of orally administered drugs. Pharm Res. 2009;26:2039-54.
30. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29-36.
31. Fawcett T. An introduction to ROC analysis. Patttern Recogn Lett. 2006;27:861-74.
32. Metz CE. Basic principles of ROC analysis. Semin Nucl Med. 1978;8:283-98.
33. Bewick V, Cheek L, Ball J. Statistics review 13: receiver operating characteristic curves. Crit Care. 2004;8:508-12.
34. Benet LZ, Broccatelli F, Oprea TI. BDDCS applied to over 900 drugs. AAPS J. 2011;13:519-47.
35. Chemical Abstracts Service. SciFinder®, version 2013, American chemical society. https://scifinder.cas.org/scifinder/view/scifinder/ scifinderExplore.jsf (accessed March 30, 2013). Calculated using Advanced Chemistry Development (ACD/Labs) Software V11.02 (© 1994-2013 ACD/Labs).
36. Shanks N, Greek R, Greek J. Are animal models predictive for humans? Philosophy, Ethics, and Humanities in Medicine. 2009;4:2.
37. Chiou WL, Jeong HY, Chung SM, Wu TC. Evaluation of using dog as an animal model to study the fraction of oral dose absorbed of 43 drugs in humans. Pharm Res. 2000;17:135-40.
38. Pérez-Garrido A, Helguera AM, Borges F, Cordeiro MNDS, Rivero V, Escudero AG. Two new parameters based on distances in a receiver operating characteristic chart for the selection of classification models. J Chem Inf Model. 2011;51:2746-59.
39. Langdon WB, Barrett SJ. Genetic programming in data mining for drug discovery. In Ghoshand A, Jain L (eds), Evolutionary computation in data mining, Vol. 163, Springer Berlin Heidelberg; 2005. p. 211-235.